Matthew Kalady is Chief of Colorectal Surgery and Medical Director of the Clinical Cancer Genetics Program at Ohio State University. He has an active clinic practice treating patients with hereditary colorectal cancer syndromes and an extensive track record in both clinical and scientific publications on hereditary CRC syndromes. He was previously Director of the Sanford R Weiss Center for Hereditary Colorectal Neoplasia at the Cleveland Clinic, and has also served as the President of the Collaborative Group of the Americas on Hereditary Colorectal Cancer (2013-14).

Susan Parry is Associate Professor of Gastroenterology specialising in familial gastrointestinal cancers. She is the Clinical Director of the New Zealand Familial Gastrointestinal Cancer Service, and Clinical Director of the Ministry of Health Bowel Cancer Programme. Susan is a past President of the New Zealand Society of Gastroenterology and has been a member of InSiGHT since it began. She was a member of the predecessor organisations, the LCPG and ICG-HNPCC. Susan has been involved as an investigator in the Australasian Colorectal Cancer Family Study-Colon CFR for many years and has a research interest in the Serrated Polyposis Syndrome.

Ian Frayling is Consultant in Genetic Pathology in Cardiff, Wales. His work now concentrates on mutation interpretation and systematic testing of incident cancers to identify hereditary cases. He is also an assessor for the UK National External Quality Assessment Scheme in Immunohistochemistry. He is a founder member of InSiGHT, InSiGHT’s Variant Interpretation Committee, and the Mallorca Group.

Andrew Latchford is Consultant Gastroenterologist at St Mark's Hospital and Honorary Senior Lecturer at Imperial College, London. He is Assistant Director of the St Mark's Hospital Polyposis Registry and currently supervises research on upper GI tract disease in polyposis syndromes, pouch polyps in FAP, serrated polyposis syndrome and identification/management outcomes in Lynch syndrome. He was an expert advisor to NICE in the development of guidelines for universal tumour MMR testing.

Gabriel Capella is Director of the Hereditary Cancer Program at the Catalan Institute of Oncology. He trained as a general and digestive surgeon in Barcelona, and is also accredited in Human Genetics by the Spanish Society of Human Genetics. His research focuses in the study of the genetic basis of gastrointestinal cancer with a particular interest in hereditary colorectal cancer.

Nicoline Hoogerbrugge is Professor in Hereditary Cancer at Radboud University Medical Center, Nijmegen. She has been directly involved in identification of several genes involved in hereditary colorectal cancer, including EPCAM, BUB1, BUB3, FOCAD and recently NTHL1. She also works on dendritic cell vaccinations for cancer prevention in healthy carries of a Lynch syndrome mutation.

Brandie Heald Leach is a genetic counsellor in the Genomic Medicine Institute and Sanford R Weiss Center for Hereditary Colorectal Neoplasia at Cleveland Clinic. She coordinates the Cleveland Clinic Universal Lynch Syndrome Screening Program and conducts research on the hamartomatous polyposis syndromes. She was on the board for Hereditary Colon Cancer Takes Guts, and is past president of the Collaborative Group of the Americas on Hereditary Colorectal Cancer. She is currently on the Board of Directors for the Lynch Syndrome Screening Network.

Patrick Lynch is Professor of Medicine, Department of Gastroenterology, Hepatology, Nutrition, University of Texas MD Anderson Cancer Centre. He has been a member of InSiGHT since its inception and was Co-chair 2009-11. He was a member of the predecessor organizations, the LCPG and ICG-HNPCC. His current interest is the development of a web-based platform for communication of risk information within mutation-positive families. He ran the 2016 New York Marathon to raise funds for InSiGHT.

Finlay Macrae is Professor in the Department of Medicine, University of Melbourne, Australia and Head of Colorectal Medicine and Genetics at The Royal Melbourne Hospital. He was a founding member of the antecedent Leeds Castle Polyposis Group, and instigated creation of the InSiGHT MMR database, its Variant Interpretation Committee, and the association with the Human Variome Project.

Allan Spigelman is Professor of Surgery at the University of New South Wales, and Director of St Vincent's Hereditary Cancer Clinic. He described the most widely used classification for upper gastrointestinal polyposis in FAP patients while a research fellow at St Mark’s Hospital. He has gone on to establish cancer genetic clinics across his state in Australia, and remains active in the cancer genetic research area. He was Chair of InSiGHT council and hosted the biennial meeting of InSiGHT in Cairns in 2013.